Reuters logo
BRIEF-Ligand enters commercial license and supply agreements with Marinus Pharmaceuticals for captisol-enabled Ganaxolone
April 5, 2017 / 3:39 PM / 6 months ago

BRIEF-Ligand enters commercial license and supply agreements with Marinus Pharmaceuticals for captisol-enabled Ganaxolone

April 5 (Reuters) - Ligand Pharmaceuticals Inc

* Ligand enters commercial license and supply agreements with Marinus Pharmaceuticals for captisol-enabled Ganaxolone

* LIGAND PHARMACEUTICALS -Marinus is preparing to initiate clinical trials with captisol-enabled Ganaxolone IV in patients with PPD and Status Epilepticus Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below